E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Psoriatic Arthritis (PsA) is an inflammatory arthritis. PsA is a highly heterogenous disease with a proportion of participants having mild non-progressive disease. Well validated prognostic factors in PsA can identify these Participants including number of active joints, systemic inflammation levels, radiographic damage and functional ability at presentation. There is little research addressing outcomes and treatment options for mild disease. |
|
E.1.1.1 | Medical condition in easily understood language |
Psoriatic arthritis causes inflammation in and around the joints. It usually affects people who already have psoriasis, a skin condition that causes a red, scaly rash. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037160 |
E.1.2 | Term | Psoriatic arthritis |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the feasibility of conducting of a future definitive trial to establish whether a subgroup of participants with mild PsA can be safely and effectively managed without DMARDs. The study will assess: 1. The proportion of participants referred to the PsA clinic who meet the inclusion criteria (with this mild disease phenotype as defined by oligoathritis, no poor prognostic factors and PSAID ≤4) 2. The proportion of participants willing to consent to the study indicating that they find the intervention acceptable 3. The proportion of participants not offered DMARD therapy during the 48 week trial period (DMARD therapy will be offered if participants have active disease despite 2 doses of glucocorticoids within a 6 month period)
|
|
E.2.2 | Secondary objectives of the trial |
To develop the design of a future definitive trial to establish whether a subgroup of patients with mild PsA can be safely and effectively managed without DMARDs. |
|
E.2.3 | Trial contains a sub-study | No |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
|
E.3 | Principal inclusion criteria |
This trial will recruit adult participants with newly diagnosed psoriatic arthritis who have not previously received treatment with synthetic or biological DMARDs for their articular disease. For this trial, only participants with mild disease defined as low disease activity and impact will be eligible (see below.
•Participants consented to the PsA inception cohort (MONITOR-PsA) and to be approached for alternate interventional therapies. •Participants with mild disease as defined by: -Oligoarticular disease with <5 active joints at baseline assessment. -Low disease activity as defined by a PsA disease activity score (PASDAS) ≤3.2. -Low impact of disease as defined a PsA impact of disease (PSAID) ≤4. •Participant is willing and able to give informed consent for participation in the trial. •Male or female. •Aged 18 years or above. •Female Participants of child bearing potential and male Participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter if receiving DMARD therapy (excluding sulfasalazine). •Participant has clinically acceptable laboratory results within 6 weeks of enrolment: o Haemoglobin count > 8.5 g/dL o White blood count (WBC) > 3.5 x 109/L o Absolute neutrophil count (ANC) > 1.5 x 109/L o Platelet count > 100 x 109/L o ALT and alkaline phosphatase levels <3 x upper limit of normal •In the Investigator’s opinion, is able and willing to comply with all trial requirements. •Willing to allow his or her GP and consultant, if appropriate, to be notified of participation in the trial.
|
|
E.4 | Principal exclusion criteria |
The patient may not enter the trial if ANY of the following apply: • ≥1 poor prognostic factors for psoriatic arthritis, from o raised C reactive protein (CRP) defined as > 4g/dl for standard non-hsCRP o radiographic damage defined as the presence of ≥ 1 erosion on plain radiographs of the hands and feet o health assessment questionnaire (HAQ) score > 1 • Contraindications to non-steroidal anti-inflammatory drugs • Previous treatment for articular disease with synthetic DMARDs (including methotrexate, leflunomide or sulfasalazine) or biologic DMARDs (including TNF, IL12/23 or IL17 inhibitor therapies) or targeted synthetic DMARDs (PDE4 of JAK inhibitor therapies). • Female patient who is pregnant, breast feeding or planning pregnancy during the course of the trial. • Significant renal or hepatic impairment. • Scheduled elective surgery or other procedures requiring general anaesthesia during the trial. • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patients at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial. • Patients who have participated in another research trial involving an investigational product in the past 12 weeks.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
This study is a feasibility study and the primary outcome is to establish the feasibility of a future study addressing this treatment option. Specific feasibility analyses include the calculation of the proportions of: • eligible patients in the cohort over the recruitment period for POISE • eligible patients consenting into the POISE trial • patients/participants requiring escalation to DMARD therapy within the first 48 weeks.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
This will be evaluated at the end of the feasibility study after 48 weeks participation in the trial. Eligible patients and proportion consenting will be monitored thoughout. |
|
E.5.2 | Secondary end point(s) |
The secondary outcome in this study is to investigate the PASDAS response and changes in PASDAS score occurring in the patients within this small feasibility study.
The primary outcome of the future study will be the proportion of Participants achieving a good response level (reduction from baseline of >1.6 and final score of <3.2) in the PsA Disease Activity Score (PASDAS)[2]. Descriptive data on PASDAS will be collected to allow accurate sample size estimations for any future trial. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
This will be evaluated through the data collected at all of the follow-up visits. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
feasibility of future study |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS and all data has been entered and queries closed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 1 |